Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, United States.
Department of Molecular Pathology, Cleveland Clinic Foundation, Cleveland, OH, United States.
Mol Immunol. 2014 Apr;58(2):182-6. doi: 10.1016/j.molimm.2013.11.018. Epub 2013 Dec 25.
BACKGROUND: The immune response has been implicated in the control of uveal melanoma progression. Epigenetic mechanisms mediated by specific microRNAs (miRs) regulate immune responses. METHODS: Blood was drawn from six patients with uveal melanoma followed from diagnosis, at which time there was no clinical or radiographic evidence of metastasis, until metastasis manifested. Circulating T cell, natural killer (NK), natural killer T (NKT), and myeloid suppressor cell populations were assessed by flow cytometry. CD3(+), CD15(+), and CD56(+) cells were isolated using immunomagnetic beads. Plasma and cellular levels of immune regulatory miRs were determined by quantitative polymerase chain reaction assays. RESULTS: The development of metastasis was associated with decreases in circulating CD3(-)CD56(dim) NK cells and CD8(+) and double-negative CD3(+)CD56(+) NKT cells. ICOS(+)CD4(+)FoxP3(+) T regulatory cells and CD11b(+)CD14(-)CD15(+) myeloid suppressor cells increased. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were higher in the study patients at diagnosis compared to controls. Plasma levels of miR-20a, 125b, 146a, 155, and 223 increased, and miR-181a decreased when metastasis manifested. Alterations in immune regulatory miRs were also observed in CD3(+), CD15(+), and CD56(+) cell populations. CONCLUSIONS: The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
背景:免疫反应被认为与葡萄膜黑色素瘤的进展有关。特定 microRNAs(miRs)介导的表观遗传机制调节免疫反应。
方法:从六名从诊断时开始就没有临床或影像学转移证据,直到出现转移的葡萄膜黑色素瘤患者中抽取血液。通过流式细胞术评估循环 T 细胞、自然杀伤(NK)细胞、自然杀伤 T(NKT)细胞和髓系抑制细胞群体。使用免疫磁珠分离 CD3(+)、CD15(+)和 CD56(+)细胞。通过定量聚合酶链反应测定法测定免疫调节 miR 的血浆和细胞水平。
结果:转移的发展与循环 CD3(-)CD56(dim)NK 细胞和 CD8(+)和双阴性 CD3(+)CD56(+)NKT 细胞的减少有关。ICOS(+)CD4(+)FoxP3(+)T 调节细胞和 CD11b(+)CD14(-)CD15(+)髓系抑制细胞增加。与对照组相比,研究患者在诊断时的血浆 miR-20a、125b、146a、155、181a 和 223 水平较高。当转移表现出来时,血浆 miR-20a、125b、146a、155 和 223 的水平升高,而 miR-181a 降低。在 CD3(+)、CD15(+)和 CD56(+)细胞群体中也观察到免疫调节 miR 的变化。
结论:葡萄膜黑色素瘤转移的发展与肿瘤免疫监测减弱相一致的免疫效应细胞和调节细胞的变化有关。这些变化与血浆和细胞水平免疫调节 miR 的变化有关。结果可能有助于指导葡萄膜黑色素瘤的免疫治疗和生物标志物开发。
Clin Exp Metastasis. 2016-12
Clin Epigenetics. 2016-7-22
Invest Ophthalmol Vis Sci. 2009-9
Cancer Immunol Immunother. 2019-5-3
Invest Ophthalmol Vis Sci. 2009-6
Invest Ophthalmol Vis Sci. 1995-2
Invest Ophthalmol Vis Sci. 2006-3
Front Mol Biosci. 2025-5-8
Front Cell Dev Biol. 2024-8-2
Front Immunol. 2024
Front Cell Dev Biol. 2022-12-22
Int J Mol Sci. 2022-11-25
Immunol Rev. 2013-5
J Biomed Biotechnol. 2012
Invest Ophthalmol Vis Sci. 2012-6-5
Int J Neurosci. 2012-5-1
J Allergy Clin Immunol. 2011-9-13